Prediction of First-in-Human Dose of Chimeric Antigen Receptor-T (CAR-T) Cells from Mice

被引:0
|
作者
Mahmood, Iftekhar [1 ]
机构
[1] Mahmood Clin Pharmacol Consultancy LLC, 1709 Piccard DR, Rockville, MD 20850 USA
关键词
PARAMETERS; SELECTION; HUMANS;
D O I
10.1007/s13318-024-00918-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and ObjectiveCurrently, there is no available method for the prediction of first-in-human (FIH) dose for chimeric antigen receptor-T (CAR-T) cells. The objective of this work was to predict the FIH dose of CAR-T cells from different doses given to mice.MethodsIn this study, six scaling methods were evaluated for the prediction of FIH dose for CAR-T cells. The methods were body weight-based fixed exponents such as 1.0 and 0.75, human equivalent dose (HED) using exponents 0.33, two modified HED methods such as using total animal dose (in place of per kg basis) and body surface area in place of body weight using total animal dose with exponent 0.33 and a physiological factor derived from physiological parameters. The FIH doses of six CAR-T cells were predicted in this study. The predicted human doses were compared with the recommended human dose by the US-FDA for four CAR-T cell products, and the literature data were used for the remaining two CAR-T cells.ResultsThe results indicated that the two modified HED methods and physiological factor are the best and reliable methods for the prediction of FIH dose for CAR-T cells.ConclusionsThe proposed methods are simple and accurate in their predictive power and can be used on a spreadsheet.
引用
收藏
页码:715 / 722
页数:8
相关论文
共 50 条
  • [1] Chimeric Antigen Receptor-T (CAR-T) Cells as "Living Drugs": A Clinical Pharmacist Perspective
    Murnane, Ciara
    Gardiner, Nicola
    Crehan, Olga
    Bacon, Christopher L.
    McHugh, Ruth
    Gilmer, John F.
    Mantalaris, Athanasios
    Panoskaltsis, Nicki
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2024, 2024
  • [2] A new era in myeloma: the advent of chimeric antigen receptor-T (CAR-T) cells and bispecific antibodies
    Ho, P. Joy
    Li, Eric W.
    INTERNAL MEDICINE JOURNAL, 2025,
  • [3] Chimeric antigen receptor-t cells (CAR-T) horizon scanning: Emerging targets in oncology and hematology
    Dardonville, Quentin
    Davoine, Claire
    Dahan, Muriel
    Grosjean, Ghislain
    Bermudez, Elisabeth
    Ifrah, Norbert
    Negellen, Sophie
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] TIME TO APPROVAL OF CHIMERIC ANTIGEN RECEPTOR-T CELLS (CAR-T) THERAPIES AMONG NORDIC COUNTRIES
    Menon, J.
    Madaj, K.
    De Cock, E.
    Vossen, C.
    VALUE IN HEALTH, 2023, 26 (06) : S224 - S224
  • [5] Chimeric Antigen Receptor beyond CAR-T Cells
    Qin, Vicky Mengfei
    D'Souza, Criselle
    Neeson, Paul J.
    Zhu, Joe Jiang
    CANCERS, 2021, 13 (03) : 1 - 16
  • [6] A narrative review of chimeric antigen receptor-T (CAR-T) cell therapy for lung cancer
    Liu, Yujia
    He, Yayi
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (09)
  • [7] Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
    Galli, Eugenio
    Bellesi, Silvia
    Viscovo, Marcello
    Sora, Federica
    Hohaus, Stefan
    Piccirillo, Nicola
    Laurenti, Luca
    Chiusolo, Patrizia
    De Stefano, Valerio
    Sica, Simona
    Zini, Gina
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2021, 13
  • [8] CAR-T cells: Lymphocytes that express a chimeric antigen receptor
    Chabannon, C.
    Bouabdallah, R.
    Furst, S.
    Granata, A.
    Saillard, C.
    Vey, N.
    Mokart, D.
    Fougereau, E.
    Lemarie, C.
    Mfarrej, B.
    Blaise, D.
    Calmels, B.
    REVUE DE MEDECINE INTERNE, 2019, 40 (08): : 545 - 552
  • [9] First-in-human trial of bispecific CAR-T cells
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2020, 19 (12) : 838 - 838
  • [10] Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies
    Cooper, Mathew L.
    DiPersio, John F.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (04)